On July 29, 2024, MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced that its molecular glue project, MRANK-103, targeting the MYC signaling pathway and designed to regulate eukaryotic translation and transcription factors, has completed the nomination of preclinical candidate (PCC) and begun the IND-Enabling studies.
Leveraging MindRank's cutting-edge AI-driven molecular glue rational design platform, ProtaG™, this initiative has successfully pinpointed potential drug candidates aimed at tackling various forms of cancer, such as CDK4/6-resistant breast cancer, colorectal cancer, lung cancer, and gastric cancer. These are areas where current treatments are either non-existent or fall short of expectations. MRANK-103 marks the fifth (PCC) to be designated by MindRank, showcasing the company's commitment to advancing cancer therapies.
Preclinical studies have shown that the drug candidates exhibit potent degradation capabilities with target degradation efficiency approaching 100% and a DC50 at picomolar activity levels. Cellular models have demonstrated significant efficacy and exceptional blood-brain barrier penetration. It is expected to be used for lung cancer, breast cancer, and their brain metastases, demonstrating strong anti-tumor cell proliferation activity in various models, including breast cancer, non-small cell lung cancer, and small cell lung cancer, particularly against MYC-High tumors, with favorable pharmacokinetics and safety profiles.
The original news link in Chinese: